COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Anemia
Related studies linked through entity extraction aliases.
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
- Status
- TERMINATED
- Phase
- PHASE2
Timing of Cord Clamping and Neonatal Hemoglobin
- Status
- WITHDRAWN
- Phase
- NA
Liberal Versus Restrictive Transfusion Guidelines for Preterm Infants
- Status
- COMPLETED
- Phase
- NA
Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
- Status
- COMPLETED
- Phase
- PHASE2
STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients
- Status
- TERMINATED
- Phase
- PHASE3
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.
- Status
- COMPLETED
- Phase
- PHASE2
A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.
- Status
- COMPLETED
- Phase
- PHASE3
A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Mircera in Anemic Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
- Status
- COMPLETED
- Phase
- PHASE2
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
- Status
- COMPLETED
- Phase
- PHASE3
(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
- Status
- TERMINATED
- Phase
- PHASE3
A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)
- Status
- TERMINATED
- Phase
- PHASE4
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
- Status
- COMPLETED
- Phase
- PHASE2
Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia
- Status
- COMPLETED
- Phase
- PHASE2
Observational Study of Iron Metabolism in Anemia in ICU and Post-Operative Patients
- Status
- COMPLETED
- Phase
- N/A